Skip to Content

Interferon Beta-1b

In the US, Interferon Beta-1b (interferon beta-1b systemic) is a member of the drug class interferons and is used to treat Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Colorectal Cancer and Multiple Sclerosis.

US matches:



CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Biological response modifier, BRM


Treatment of multiple sclerosis, MS

Foreign Names

  • Interferonum beta-1b (Latin)
  • Interferon beta-1b (German)
  • Intérferon bêta-1b (French)
  • Interferón beta-1b (Spanish)

Generic Names

Brand Names

  • Betaferon
    Bayer, Bosnia & Herzegowina; Bayer, Belgium; Bayer, Chile; Bayer, China; Bayer, Colombia; Bayer, Costa Rica; Bayer, Czech Republic; Bayer, Denmark; Bayer, Dominican Republic; Bayer, Ecuador; Bayer, Spain; Bayer, United Kingdom; Bayer, Greece; Bayer, Guatemala; Bayer, Hong Kong; Bayer, Honduras; Bayer, Croatia (Hrvatska); Bayer, Hungary; Bayer, Ireland; Bayer, Italy; Bayer, South Korea; Bayer, Lithuania; Bayer, Nicaragua; Bayer, New Zealand; Bayer, Panama; Bayer, Philippines; Bayer, Poland; Bayer, Portugal; Bayer, Sweden; Bayer, Slovakia; Bayer, El Salvador; Bayer, Turkey; Bayer Australia Ltd, Australia; Bayer Health Care, Malaysia; Bayer HealthCare, Finland; Bayer HealthCare, Russian Federation; Bayer Pharma, Austria; Bayer Pharma, Israel; Bayer Pharma, Macedonia; Bayer Pharma AG, Norway; Bayer Santé, France; Bayer Schering, Georgia; Bayer Schering, Serbia; Bayer Schering, Singapore; Bayer Schering, Tunisia; Bayer Schering, Taiwan; Bayer Schering, South Africa; Bayer Thai Co Ltd, Thailand; Bayer Vital, Germany; Bayer Yakuhin, Japan; Bayer-Schering, Romania; Eurim-Pharm, Austria; Haemato Pharm, Austria; Schering, Brazil; Schering, Iceland; Schering, Oman
  • Betaferone
    Bayer, Latvia
  • Betaseron
    Bayer, Canada; Bayer HealthCare, United States
  • Extavia
    Bayer, Slovakia; Novartis, Belgium; Novartis, Czech Republic; Novartis, Denmark; Novartis, Finland; Novartis, France; Novartis, Greece; Novartis, Croatia (Hrvatska); Novartis, Hungary; Novartis, Lithuania; Novartis, Norway; Novartis, Poland; Novartis, Romania; Novartis, Sweden; Novartis, United States; Novartis Europharm Limited, Latvia; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Pharma, Germany; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom
  • Uribeta
    Probiomed, Dominican Republic; Probiomed, Guatemala; Probiomed, Honduras; Probiomed, Mexico; Probiomed, El Salvador


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.